Methestrol
Chemical compound
![]() | |
Clinical data | |
---|---|
Trade names | Meprane |
Other names | Methoestrol; Metestrol; Promethestrol; Promethoestrol; Dimethylhexestrol |
Drug class | Nonsteroidal estrogen |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C20H26O2 |
Molar mass | 298.426 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
|
Methestrol (INNTooltip International Nonproprietary Name; brand name Meprane) or methoestrol, also known as promethestrol or promethoestrol (BANTooltip British Approved Name) or as dimethylhexestrol, is a synthetic nonsteroidal estrogen of the stilbestrol group related to diethylstilbestrol which is no longer marketed.[1][2][3][4][5][6][7]
A related drug is methestrol dipropionate (or promethestrol dipropionate) (brand name Meprane Dipropionate).[8][9][10][11][12][13]
See also
- Benzestrol
- Dienestrol
- Hexestrol
References
- ^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 608–. ISBN 978-0-412-46630-4.
- ^ Brucker MC, King TL (8 September 2015). Pharmacology for Women's Health. Jones & Bartlett Learning. pp. 640–. ISBN 978-1-284-10811-8.
- ^ Sturgis SH (April 1947). "Preliminary clinical report on a new synthetic estrogen, meprane". American Journal of Obstetrics and Gynecology. 53 (4): 678–681. doi:10.1016/0002-9378(47)90289-5. PMID 20291241.
- ^ Coulton D (August 1947). "Meprane an effective estrogen for inhibition and suppression of lactation". American Journal of Obstetrics and Gynecology. 54 (2): 289–295. doi:10.1016/s0002-9378(16)39536-9. PMID 20257315.
- ^ Coulton D, Sewall CW (September 1948). "Meprane in the treatment of the menopausal syndrome; an evaluation of estrogenic efficiency and toxicity". American Journal of Obstetrics and Gynecology. 56 (3): 541–548. doi:10.1016/0002-9378(48)90643-7. PMID 18877188.
- ^ Lin HA (August 1947). "A clinical study of a new synthetic estrogen". American Journal of Obstetrics and Gynecology. 54 (2): 296–300. doi:10.1016/s0002-9378(16)39537-0. PMID 20257316.
- ^ Jones GF (November 1949). "Physiology and management of the climacteric". California Medicine. 71 (5): 345–348. PMC 1520053. PMID 15390574.
- ^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. Taylor & Francis. pp. 1298–. ISBN 978-0-412-46630-4.
- ^ Thomas JA, Keenan EJ (6 December 2012). "Estrogens and Antiestrogenic Drug". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 150–. ISBN 978-1-4684-5036-1.
- ^ "Female Reprodiction – Ovary". Essential of Endocrinology and Reproductive Physiology. Allied Publishers. 1985. pp. 85–. GGKEY:HLNJ1BHUKW2.
- ^ Modell W (21 November 2013). Drugs in Current Use 1958. Springer. pp. 114–. ISBN 978-3-662-40303-7.
- ^ Dubin (6 December 2012). Emergency Psychiatry for the House Officer. Springer Science & Business Media. pp. 155–. ISBN 978-94-011-6690-4.
- ^ Forsberg JG (22 October 2013). "Induction of Conditions Leading to Cancer in the Genital Tract by Estrogen During the Differentiation Phase of the Genital Epithelium". In Raspé G (ed.). Hormones and Embryonic Development: Advances in The Biosciences. Elsevier Science. pp. 141–. ISBN 978-1-4831-5171-7.
- v
- t
- e
Estrogens and antiestrogens
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Estrogen receptor modulators
- Androgens and antiandrogens
- Progestogens and antiprogestogens
- List of estrogens
![]() | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e